SCHEMBL6715577

SCHEMBL6715577

Cc1ccccc1NC(=O)C(N)c1ccc(F)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
KCNQ2 O43526 1/20 0.46
POLB P06746 3/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
HTT P42858 4/20 0.44
DDX3X O00571 2/20 0.44
KDM4C Q9H3R0 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HPGD P15428 3/20 0.44
ALDH1A1 P00352 1/20 0.44
PGR P06401 1/20 0.43
SCN1A P35498 1/20 0.43
SCN2A Q99250 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713811 0.85 LMNA (0.54) LMNASMN1; SMN2NPSR1HTTCYP3A4
SCHEMBL6718687 0.81 RAB9A (0.55) LMNASMN1; SMN2NPSR1POLBNPC1
SCHEMBL28609335 0.81 RAB9A (0.55) LMNASMN1; SMN2NPSR1POLBNPC1
SCHEMBL6718773 0.81 RAB9A (0.55) LMNASMN1; SMN2NPSR1POLBNPC1
SCHEMBL6719271 0.78 GAA (0.60) SMN1; SMN2KCNQ2POLBRAB9AHTT
SCHEMBL3729720 0.76 CES2 (0.44) LMNASMN1; SMN2KCNQ2MAPT
Formic Acid SCHEMBL6717292 0.76 CYP1A2 (0.53) LMNASMN1; SMN2NPSR1POLBNPC1
Formic Acid SCHEMBL6715482 0.76 CYP1A2 (0.53) LMNASMN1; SMN2NPSR1POLBNPC1
SCHEMBL6716864 0.74 PGR (0.47) LMNAPOLBNPC1RAB9AHTT
SCHEMBL8346804 0.73 NPC1 (0.60) LMNAPOLBNPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 LMNA 3700/4885SMN1; SMN2 1805/4885NPSR1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.